Organization · Venture Capital
Vesalius Biocapital IV
Vesalius Biocapital IV is a Luxembourg-based venture capital firm focused on investing in later-stage life sciences companies across drug development, medical devices, and digital health sectors in Europe.
Overview
What Vesalius Biocapital IV does
What Vesalius Biocapital IV is
Vesalius Biocapital IV is a Luxembourg-based venture capital firm focused on investing in later-stage life sciences companies across drug development, medical devices, and digital health sectors in Europe.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2023
- Approximate age
- About 3 years
- Structured capabilities
- Funder
- Last reviewed
- May 1, 2026
Official channels
Find Vesalius Biocapital IV elsewhere
Open the official website or a supported primary organization account.
Capability profile
Vesalius Biocapital IV as a funder
Investment thesis
Vesalius Biocapital IV invests in first-in-class and best-in-class European life-sciences companies, focusing on HealthTech and Biopharma. The firm targets late pre-clinical to early clinical stages and early commercialization, emphasizing strong intellectual property and unmet medical needs.
Focus narrative
Vesalius Biocapital IV invests primarily in HealthTech and Biopharma sectors. The firm emphasizes early commercialization and growth in HealthTech, targeting improvements in diagnosis and patient outcomes, while in Biopharma, it focuses on late pre-clinical to early clinical stages, seeking novel therapeutic approaches to address unmet medical needs.
Value beyond capital
Vesalius Biocapital IV adds value to its portfolio companies through strategic guidance, access to a network of industry experts, and support in navigating the complexities of the healthcare market. The firm emphasizes follow-on investments to ensure continued growth and development.
Terms and economics
- Typical check
- $250,000–$15,000,000
- Sweet spot
- $10,000,000
Focus and fit
- Stages
- Series A · Series B · Series C · Growth Equity
- Sectors
- Biotech · Healthcare · Digital Health · Medical Devices · Diagnostics
- Regions
- EuropeNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 6
Portfolio context
Notable portfolio companies include: HepaRegeniX GmbH: Developing therapies for liver diseases. inHEART: Creating 3D heart models for cardiac procedures. Cognivia: Enhancing clinical trials with AI-driven patient psychology quantification. Nutrium: A corporate nutrition solution for chronic disease management. ENYO Pharma: Developing therapeutics for kidney and metabolic diseases. Inflammatix: Focused on molecular diagnostics for acute infections.
Common questions
What to know about Vesalius Biocapital IV
Upseed classifies Vesalius Biocapital IV under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.